Cho 2011

Methods	Randomised trial conducted in Republic of Korea 2 treatment arms: CBZ (controlled release) and LEV
Participants	Participants with newly diagnosed partial epilepsy who had their first seizure between 6 and 1 month prior to entry into the trial and had not taken any AEDs previously. Number completing the trial: CBZ = 15, LEV = 16 (number randomised not stated) 22 male participants (71%) 100% of participants had partial epilepsy Mean age (SD, range): CBZ = 29.8 (9.31, 15‐49), LEV = 31.4 (15.3, 15‐66) years
Interventions	Monotherapy with CBZ or LEV Treatment regimens were CBZ = 400 mg/d and LEV = 1000 mg/d Trial duration 4‐6 weeks, range of follow‐up not stated
Outcomes	Change in overnight PSG scores (sleep latency, REM sleep latency, total sleep time, sleep efficiency, percentage of each sleep stage, arousal index, and Wake time After Sleep Onset) from baseline after 4‐6 weeks of treatment Change in sleep questionnaires (sleep diaries, the Pittsburg Sleep Quality Index, the Korean version of the Epworth Sleepiness Scale, Beck’s depression inventory‐2 and the Hospital Anxiety Scale) and National Hospital Seizure Severity Scale (NHS3) from baseline after 4‐6 weeks of treatment
Notes	IPD could not be provided for the trial due to concerns over institutional review board approval (information provided by corresponding author). Outcomes chosen for this review were not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Trial described as randomised, no further information provided
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information provided
Blinding of outcome assessment (detection bias) All outcomes	Low risk	PSG scores were interpreted by a certified physician who was blinded to treatment
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Number randomised not stated, results provided only for those who completed the trial
Selective reporting (reporting bias)	Low risk	All sleep, efficacy, and tolerability outcomes specified in the methods sections were reported well in the results section. No protocol was available. Outcomes chosen for this review were not reported
Other bias	Low risk	None identified